A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular events in people with established CVD and overweight or obesity without ...
ELSE NUTRITION HOLDINGS INC. ("Else" or the "Company"), announces that further to its news release of March 21, 2025, it is rescheduling the planned business update conference call originally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback